Other Information
+Added: Departure of Directors or Certain Officers;
+Added: Election of Directors;
+Added: Appointment of Certain Officers;
+Added: Compensatory Arrangements of Certain Officers
+Added: On May 12, 2025, Alan J.
+Added: notified us of his retirement as our executive vice president, innovation and chemical sciences, effective July 31, 2025, and Kristen L.
+Added: Alexander notified us of her retirement as our vice president, finance and accounting (in which capacity, Ms.
+Added: Alexander functions as our principal accounting officer), effective May 30, 2025.
+Added: Effective as of the date of Ms.
+Added: Alexander’s retirement, Scott M.
+Added: Coiante will assume the function of our principal accounting officer.
+Added: Coiante, 58, has been our senior vice president and chief financial officer (in which capacity, Mr.
+Added: Coiante functions as our principal financial officer) since January 2025.
+Added: Coiante previously served for ten years in senior leadership positions at Agile Therapeutics, Inc., most recently as senior vice president, chief financial officer from 2011 to 2019 and from August 2023 to August 2024.
+Added: Coiante also served as senior vice president, chief financial officer at Aprea Therapeutics, Inc.
+Added: from 2019 to March 2023 and in a series of senior financial and accounting positions with Medarex, Inc.
+Added: and Ernst & Young LLP prior to joining Agile Therapeutics.
+Added: Coiante is a certified public accountant and received his B.S.
+Added: from Villanova University.
Insider Trading Arrangements
−Removed: During the three months ended September 30, 2024, none of our directors or executive officers adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
−Removed: 10.1 — Separation Agreement, dated September 13, 2024, with Jeffrey L.
−Removed: Wade (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K dated September 13, 2024 and incorporated by reference herein).
−Removed: 10.2 — Consulting Agreement, dated September 13, 2024, with Jeffrey L.
−Removed: Wade (filed as Exhibit 10.2 to the Company’s Current Report on Form 8-K dated September 13, 2024 and incorporated by reference herein).
+Added: During the three months ended March 31, 2025, none of our directors or executive officers adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
+Added: *†10.1 — Exclusive License Agreement, dated March 27, 2025 , with Novo Nordisk A/S
+Added: †10.2 — Seventh Amendment to Loan and Security Agreement, dated March 27, 2025 , with Oxford Finance, LLC and the lenders listed therein (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K dated March 27, 2025 and incorporated by reference herein).
— Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
10 unchanged sentences
* Filed herewith.
+Added: † Certain information (indicated by “[**]”) has been excluded from this exhibit because it is both not material and would likely cause competitive harm to the Company if publicly disclosed.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Lexicon Pharmaceuticals, Inc.
−Removed: November 13, 2024 By:
+Added: May 14, 2025 By:
/s/ Michael S.
Chief Executive Officer
−Removed: November 13, 2024 By:
−Removed: /s/ Kristen L.
−Removed: Vice President, Finance and Accounting
+Added: May 14, 2025 By:
+Added: Senior Vice President and Chief Financial Officer
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.